Supernus Pharmaceuticals, Inc. (SUPN)
| Market Cap | 1.56B |
| Revenue (ttm) | 477.29M |
| Net Income (ttm) | 129.31M |
| Shares Out | 52.66M |
| EPS (ttm) | 2.41 |
| PE Ratio | 12.84 |
| Forward PE | 20.16 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 24 |
| Last Price | $30.96 |
| Previous Close | $29.58 |
| Change ($) | 1.38 |
| Change (%) | 4.67% |
| Day's Open | 29.72 |
| Day's Range | 29.72 - 31.26 |
| Day's Volume | 566,920 |
| 52-Week Range | 13.12 - 31.99 |
ROCKVILLE, Md., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatmen...
If you pick securities whose earnings return is more than twice that of the 20-year high-quality market corporate bonds, you could increase your probability to unearth value opportunities, in ...
ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...
It has been eight months since we last looked in on a promising biopharma concern named Supernus Pharmaceuticals. Some significant news has posted since then including some recently disclosed ...
The company announced positive results from a clinical trial.
The shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) are up 17.7% at $26.50 at last check, after its experimental drug for attention deficit hyperactivity disorder (ADHD), SPN-812, met its...
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) announced Monday that its SPN-812 — a commercial treatment for patients with Attention Deficit Hyperactivity Disorder (ADHD), exhibited positive top...
Supernus Pharmaceuticals Inc. shares jumped more than 20% in after-hours trading Tuesday after the company revealed positive results from a study of its potential drug for attention deficit hy...
ROCKVILLE, Md., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2021.
Let's see if Supernus Pharmaceuticals (SUPN) stock is a good choice for value-oriented investors right now from multiple angles.
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (“Supernus or the “Company”) (NASDAQ: SUPN). Such inv...
LOS ANGELES--(BUSINESS WIRE)---- $SUPN #classaction--The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN) ...
BENSALEM, Pa.--(BUSINESS WIRE)---- $SUPN #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
ROCKVILLE, Md., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...
LOS ANGELES--(BUSINESS WIRE)---- $SUPN #CLASSACTION--Glancy Prongay & Murray LLP, Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc (SUPN) on Behalf o...
ROCKVILLE, Md., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...
NEW YORK, Nov. 11, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus or the "Company") (NASDAQ: SUPN). Such investo...
ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2020 Results - Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2020 Results - Earnings Call Transcript
Supernus (SUPN) delivered earnings and revenue surprises of 174.07% and 18.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ROCKVILLE, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...
ROCKVILLE, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...
Investors who are looking for high return investments might be interested in the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt's method) a...
Greg Patrick to Retire as Chief Financial Officer Greg Patrick to Retire as Chief Financial Officer
Supernus is solidly on track for a new record of net sales this year and is still generating huge amounts of free cash flow.
These stocks are just temporarily inconvenienced large caps in the making.
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.
ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...
ROCKVILLE, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...
ROCKVILLE, Md., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2020 Results - Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2020 Results - Earnings Call Transcript
Supernus (SUPN) delivered earnings and revenue surprises of 85.71% and 0.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
ROCKVILLE, Md., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment...
ROCKVILLE, Md., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment...
Supernus (SUPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gold, silver, miners/GSMs outperformed nicely in Q2, and should continue to do extremely well going forward.
ROCKVILLE, Md., June 26, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment...
As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.
Creates leading CNS portfolio with five marketed products, two product candidates in late-stage development, and robust pipeline Creates leading CNS portfolio with five marketed products, two ...
ROCKVILLE, Md., May 15, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment ...
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2020 Results - Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2020 Results - Earnings Call Transcript
Supernus (SUPN) delivered earnings and revenue surprises of 33.33% and 11.47%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ROCKVILLE, Md., April 28, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About SUPN
Supernus Pharmaceuticals, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in the United States. The company offers Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and in children 6 to 17 years of age; and Trokendi XR, an extended release topiramate, which is used for the prophylaxis of migraine headache, as well as for the treatment of epilepsy. Its prod... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date May 1, 2012 |
| CEO Jack Khattar | Employees 464 |
| Stock Exchange NASDAQ | Ticker Symbol SUPN |
Financial Performance
In 2019, SUPN's revenue was $392.76 million, a decrease of -3.95% compared to the previous year's $408.90 million. Earnings were $113.06 million, an increase of 1.86%.
Analyst Forecasts
According to 4 analysts, the average rating for SUPN stock is "Buy." The 12-month stock price forecast is 31.00, which is an increase of 0.13% from the latest price.